Wall Street Zen Downgrades Palisade Bio (NASDAQ:PALI) to Sell

Palisade Bio (NASDAQ:PALI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Citigroup reissued a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $16.00.

Palisade Bio Stock Performance

NASDAQ:PALI opened at $1.83 on Friday. Palisade Bio has a one year low of $0.53 and a one year high of $2.59. The stock has a market cap of $272.67 million, a PE ratio of -0.86 and a beta of 1.54. The stock has a 50 day moving average price of $1.90 and a 200 day moving average price of $1.22.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). As a group, analysts predict that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Palisade Bio stock. Armistice Capital LLC increased its stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 144,764 shares of the company’s stock after purchasing an additional 39,397 shares during the quarter. Armistice Capital LLC owned 3.29% of Palisade Bio worth $99,000 at the end of the most recent quarter. 11.79% of the stock is owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.